Want to see HK:9955 full AI Analyst Report?
Top Page
ClouDr Group Limited
(9955)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.48
▼(-52.20% Downside)
Action:Reiterated
Date:09/06/26
Overall score is constrained primarily by weak financial performance (sharp revenue contraction and continued large losses, with free cash flow still negative). Technicals add further pressure due to a clear downtrend and negative momentum signals. Valuation is also hampered by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Balance sheet stabilization
Positive equity and moderate leverage represent a meaningful improvement from the negative-equity period in 2020–2021. This provides a more stable financial base, although persistent losses could still weaken capital strength if the improvement is not maintained.
Negative Factors
Sharp revenue contraction
A substantial revenue contraction indicates weakening business scale and reduces the base over which fixed operating costs can be absorbed. Continued shrinkage could pressure store economics, limit reinvestment capacity, and make a return to sustainable profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet stabilization
Positive equity and moderate leverage represent a meaningful improvement from the negative-equity period in 2020–2021. This provides a more stable financial base, although persistent losses could still weaken capital strength if the improvement is not maintained.
Read all positive factors
ClouDr Group Limited (9955) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$315.28M
Dividend YieldN/A
Average Volume (3M)238.14K
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue Growth-37.76%
EPS Growth60.28%
CountryHK
Employees776
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.65
Shares Outstanding645,718,800
10 Day Avg. Volume103,310
30 Day Avg. Volume238,143
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.00
Price to Sales (P/S)0.34
P/FCF Ratio-8.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
ClouDr Group Limited Business Overview & Revenue Model
Company Description
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose mete...
How the Company Makes Money
ClouDr Group Limited primarily makes money by selling healthcare products to end customers through its retail channels. Its main revenue stream is retail sales generated in physical pharmacies and via online channels, with product categories gener...
ClouDr Group Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 1.62B | 3.49B | 3.69B | 2.99B | 1.76B |
| Gross Profit | 737.81M | 775.08M | 861.67M | 909.38M | 792.10M | 570.02M |
| EBITDA | 36.91M | -495.62M | -372.34M | -208.37M | -1.58B | -4.06B |
| Net Income | -404.85M | -924.15M | -516.41M | -323.06M | -1.69B | -4.14B |
Balance Sheet | ||||||
| Total Assets | 1.47B | 1.68B | 2.84B | 2.95B | 2.83B | 2.51B |
| Cash, Cash Equivalents and Short-Term Investments | 325.51M | 449.77M | 525.84M | 595.10M | 723.17M | 1.12B |
| Total Debt | 210.16M | 288.75M | 581.24M | 469.69M | 228.67M | 9.03B |
| Total Liabilities | 1.03B | 1.20B | 1.41B | 1.18B | 953.05M | 9.66B |
| Stockholders Equity | 511.00M | 548.79M | 1.45B | 1.83B | 1.85B | -7.14B |
Cash Flow | ||||||
| Free Cash Flow | 16.70M | -65.22M | -225.19M | -263.46M | -809.87M | -755.02M |
| Operating Cash Flow | 38.19M | 82.38M | -148.39M | -140.43M | -642.63M | -666.33M |
| Investing Cash Flow | -117.09M | 9.33M | 66.87M | -38.34M | -744.94M | -155.50M |
| Financing Cash Flow | -59.78M | -32.72M | 147.99M | 171.81M | 503.55M | 1.02B |
ClouDr Group Limited Technical Analysis
Negative
1.00
Price Trends
0.52
Negative
0.59
Negative
0.75
Negative
Market Momentum
>-0.01
Negative
41.23
Neutral
9.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Negative. The current price of 1 is above the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.52, and above the 200-day MA of 0.75, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.23 is Neutral, neither overbought nor oversold. The STOCH value of 9.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9955.
ClouDr Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$5.17B | 13.03 | 7.00% | 4.49% | 6.47% | 8.10% | |
65 Neutral | HK$49.40B | 6.10 | 8.33% | 4.93% | 2.78% | 7.71% | |
57 Neutral | HK$594.00M | 10.95 | 7.70% | 6.25% | 14.28% | 0.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$315.28M | -0.66 | -76.42% | ― | -37.76% | 60.28% | |
41 Neutral | HK$416.14M | -6.62 | -273.18% | ― | 5.52% | 56.54% | |
40 Underperform | HK$891.82M | -9.64 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:9955
ClouDr Group Limited
0.50
-0.88
-63.77%
HK:0673
China Health Group
0.33
-0.11
-26.14%
HK:1099
Sinopharm Group Co
16.03
-1.63
-9.24%
HK:1931
IVD Medical Holding Limited
0.53
-10.11
-95.06%
HK:2192
Medlive Technology Co., Ltd.
7.01
-6.49
-48.08%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
-0.17
-3.07%
ClouDr Group Limited Corporate Events
ClouDr Narrows Losses But Revenue Falls Nearly 30% in First-Half 2026
Aug 27, 2026
ClouDr Group Limited reported a sharp year-on-year revenue decline for the six months ended June 30, 2026, with total revenue falling 29.5% to RMB629.2 million as both in-hospital and out-of-hospital solutions contracted across subscription, value...
ClouDr Group Sets Board Meeting to Approve 2026 Interim Results
Aug 17, 2026
ClouDr Group Limited has scheduled a board meeting for August 27, 2026, to review and approve the interim financial results for the six months ended June 30, 2026. The meeting will also address the publication of these results and any other busine...
ClouDr Group Signals Sharp Narrowing of Interim Loss on AI-Driven Turnaround
Jul 24, 2026
ClouDr Group Limited reported that its consolidated net loss for the six months ended June 30, 2026 is expected to narrow sharply to between RMB60 million and RMB10 million, from RMB642.9 million a year earlier. The board attributed this improveme...
ClouDr Details RMB639 Million Impairments and Phases Out Risky Pharma Solutions
Jun 30, 2026
ClouDr Group Limited has disclosed additional details on impairment losses totaling about RMB639.1 million for the year ended December 31, 2025, mainly tied to trade and other receivables, assets held for sale and non-current assets. The company s...
ClouDr Shareholders Back Board Mandates and Equity Incentive Refresh at 2026 AGM
Jun 30, 2026
ClouDr Group Limited reported the results of its annual general meeting held on June 30, 2026, where shareholders unanimously approved the 2025 audited financial statements and re-elected key board members, including executive director Ms. Hu Yue ...
ClouDr Group Sets 2026 AGM to Seek Director Re-Elections and New Share Mandates
Jun 9, 2026
ClouDr Group Limited has called its annual general meeting for June 30, 2026, in Nanjing, where shareholders will review the audited financial statements for the year ended December 31, 2025 and related reports. The meeting will also vote on the r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.